These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Fungal infections. Kauffman CA Proc Am Thorac Soc; 2006; 3(1):35-40. PubMed ID: 16493149 [TBL] [Abstract][Full Text] [Related]
23. [Invasive fungal infections in patients after liver transplantation]. Fischer L; Sterneck M Mycoses; 2005; 48 Suppl 1():27-35. PubMed ID: 15826284 [TBL] [Abstract][Full Text] [Related]
24. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Strasfeld L; Weinstock DM Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622 [TBL] [Abstract][Full Text] [Related]
25. Management of invasive fungal infections: a role for polyenes. Chandrasekar P J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787 [TBL] [Abstract][Full Text] [Related]
26. Posaconazole: clinical pharmacology and potential for management of fungal infections. Groll AH; Walsh TJ Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193 [TBL] [Abstract][Full Text] [Related]
31. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. Lewis RE Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618 [TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of new antifungal agents. Kauffman CA Curr Opin Microbiol; 2006 Oct; 9(5):483-8. PubMed ID: 16904366 [TBL] [Abstract][Full Text] [Related]
33. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances]. Cuenca-Estrella M Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554 [TBL] [Abstract][Full Text] [Related]
34. Role of antifungal susceptibility testing in patient management. Forrest G Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328 [TBL] [Abstract][Full Text] [Related]
35. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448 [TBL] [Abstract][Full Text] [Related]
36. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Groll AH; Walsh TJ Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576 [TBL] [Abstract][Full Text] [Related]
37. Changing epidemiology of rare mould infections: implications for therapy. Malani AN; Kauffman CA Drugs; 2007; 67(13):1803-12. PubMed ID: 17722951 [TBL] [Abstract][Full Text] [Related]
38. Fungal infections in neonates: update on prevention and treatment. Kaufman DA Minerva Ginecol; 2007 Jun; 59(3):311-29. PubMed ID: 17576407 [TBL] [Abstract][Full Text] [Related]
39. Antifungal treatment strategies in high risk patients. Rüping MJ; Vehreschild JJ; Cornely OA Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331 [TBL] [Abstract][Full Text] [Related]
40. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Slavin MA; Szer J; Grigg AP; Roberts AW; Seymour JF; Sasadeusz J; Thursky K; Chen SC; Morrissey CO; Heath CH; Sorrell T Intern Med J; 2004 Apr; 34(4):192-200. PubMed ID: 15086700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]